Mutation Clinical Trials in Guangzhou, Guangdong
17 recruitingGuangzhou, Guangdong, China
Showing 1–17 of 17 trials
Recruiting
Phase 3
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Advanced Non-small Cell Lung Cancer, HER2 Mutation
Bayer444 enrolled285 locationsNCT06452277
Recruiting
Phase 2
EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC
EGFR Activating MutationLung Cancer Non-Small Cell Cancer (NSCLC)PD-1 Antibody
Nanfang Hospital, Southern Medical University32 enrolled1 locationNCT07637448
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
Advanced Solid Tumors With MAPK Pathway Mutations
D3 Bio (Wuxi) Co., Ltd67 enrolled14 locationsNCT05886920
Recruiting
Phase 2
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
MutationLung Cancer Stage III
Sun Yat-sen University120 enrolled1 locationNCT06563999
Recruiting
Not Applicable
Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
Leptomeningeal MetastasisNSCLC (Advanced Non-small Cell Lung Cancer)EGFR Activating Mutation+1 more
Guangzhou University of Traditional Chinese Medicine42 enrolled1 locationNCT07348965
Recruiting
Phase 3
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Servier Bio-Innovation LLC136 enrolled114 locationsNCT06127407
Recruiting
Phase 1Phase 2
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Breast CancerOvarian CancerProstate Cancer+3 more
Acerand Therapeutics (Shanghai) Limited298 enrolled14 locationsNCT06380660
Recruiting
Phase 1Phase 2
A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
Advanced Solid TumorsKRAS G12D Mutations
Genfleet Therapeutics (Shanghai) Inc.407 enrolled20 locationsNCT06500676
Recruiting
Phase 1Phase 2
A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer
EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Wayshine Biopharm, Inc.100 enrolled12 locationsNCT06631989
Recruiting
Phase 2
Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study
Non-small Cell Lung Cancer (NSCLC)Leptomeningeal MetastasesBrain Metastases+2 more
Li-kun Chen70 enrolled1 locationNCT06728865
Recruiting
Phase 2
Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer
Non-small Cell Lung CancerEGFR Exon 20 Insertion Mutation
BeBetter Med Inc200 enrolled2 locationsNCT06706713
Recruiting
Phase 2
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
Relapse/RecurrenceAML, ChildhoodRefractory AML+2 more
Children's Hospital of Soochow University50 enrolled12 locationsNCT06316960
Recruiting
Phase 2
A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL
Acute Lymphoblastic LeukemiaAdult ALLPhiladelphia-Positive ALL+2 more
Nanfang Hospital, Southern Medical University67 enrolled1 locationNCT06220487
Recruiting
Phase 2
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
Li-Fraumeni SyndromePediatric Cancerp53 Mutations
Yang Li50 enrolled1 locationNCT06088030
Recruiting
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
Non-small Cell Lung Cancer (NSCLC)EGFR-TKI Resistant MutationEGFR-TKI Sensitizing Mutation+2 more
Sun Yat-sen University1,000 enrolled1 locationNCT01994057
Recruiting
Phase 2
Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation
Her-2 Negative Breast CancerHRR Gene Mutation
Ying Lin66 enrolled1 locationNCT05761470
Recruiting
Phase 1Phase 2
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
C-Met Exon 14 Mutation
Haihe Biopharma Co., Ltd.183 enrolled44 locationsNCT04270591